2000% dividend in Q4 results 2024 - Amount, record date, payment date
gland pharma dividend 2024 2000% dividend in q4 quarterly results 2024 – check amount, record date and payment date
Gland Pharma Dividend 2024, Gland Pharma Q4 Resulst 2024: Gland Pharma Limited, a generic injectable-focused pharmaceutical company, on Wednesday, May 22, 2024, declared its earnings for the fourth quarter March 31, 2023. The company has also declared a whopping 2000 per cent dividend for its shareholders in the Q4 FY24 results. A dividend is a company's reward to its investors for their investment in the business. It is paid in cash from earnings.
Gland Pharma Dividend 2024
The Board of Directors of Gland Pharma at its meeting held today, Wednesday, May 22, 2024 has recommended a final dividend of 2000 per cent per equity share. A dividend is always calculated and paid on the face value of each stock. Accordingly, 2000 per cent dividend translates into Rs 20 per equity share on the face value of Rs 1 each for the fiscal year 2023-24.
Related News |
Tata Stock Dividend: 320% payout per share - Record date today
“Recommended a final dividend of Rs. 20/- (2000%) per equity share of Rs. 1/- each for the financial year 2023-24. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 46th Annual General Meeting (AGM),” said the company in an exchange filing today.
Gland Pharma Dividend 2024 Record Date
Gland Pharma has set August 16 as the record date for determining the eligibility of shareholders' participation in the next dividend or corporate action.
“The Record Date for the purpose of the 46th Annual General Meeting and payment of final dividend, if approved by shareholders will be Friday, August 16, 2024,” the pharmaceutical company said the exchange filing.
Gland Pharma Dividend 2024 Payment Date
The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 46th Annual General Meeting (AGM), added the company.
Related News |
SBI dividend 2024: Ex-date, Record date today; are you eligible?
Gland Pharma Q4 Results 2024
Gland Pharma said its PAT (profit after tax) reported a 112.9 per cent surge to Rs 192 crore in Q4 FY24 from Rs 79 crore in Q4 FY23.
The company’s consolidated revenue surged 95.8 per cent YoY to Rs 1,537 crore in the quarter under review from Rs 785 crore in the same quarter the previous year.
Consolidated EBITDA soared 112.9 per cent YoY to Rs 359 crore from Rs 168 crore in Q4 of FY24. EBITDA margin expanded to 23.3 per cent in Q4 FY24 from 21.5 per cent in Q4 FY23.
Commenting on the results, Srinivas Sadu, MD & CEO of Gland Pharma, said, “This year marked a significant rebound for our base business, and we began an exciting new chapter as we completed our first international acquisition, Cenexi, in Europe. Despite the dynamic business landscape, we've shown resilience and delivered a performance that positions us well for continued growth and success. We see continued momentum in this segment and are optimistic about its future opportunities. The strategic rationale behind Cenexi’s acquisition remains intact, and we expect it to deliver significant value as we move forward.”
Gland Pharma Share Price
Shares of Gland Pharma on Wednesday closed at Rs 1795.50 , 0.26 per cent lower from the previous close of Rs 1800.25, as per BSE. The stock opened at Rs 1802.05 and touched an intra-day high of Rs 1830 and low of Rs 1774.70.
RISE with India - FOLLOW ET NOW WhatsApp channel!
https://whatsapp.com/channel/0029Va7OSzxA2pL8ezY1aw1K
ET NOW WhatsApp channel gives you all Stock Market Details, Money Making Ideas, IPO News, Mutual Funds SIP News, Income Tax and other news right on your mobile screen!